Headlines about RedHill Biopharma (NASDAQ:RDHL) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. RedHill Biopharma earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.5503718370609 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
A number of research analysts have recently issued reports on the company. Zacks Investment Research raised RedHill Biopharma from a “sell” rating to a “hold” rating in a research note on Wednesday, September 27th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective (up from $33.00) on shares of RedHill Biopharma in a research note on Wednesday, October 4th. Roth Capital reissued a “buy” rating and issued a $27.00 target price on shares of RedHill Biopharma in a research note on Wednesday, October 4th. Seaport Global Securities initiated coverage on shares of RedHill Biopharma in a report on Friday, October 6th. They issued a “buy” rating and a $19.00 price objective for the company. Finally, UBS Group initiated coverage on shares of RedHill Biopharma in a report on Wednesday, September 13th. They issued a “reduce” rating for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $21.10.
RedHill Biopharma (RDHL) opened at $5.36 on Thursday. RedHill Biopharma has a 1-year low of $4.30 and a 1-year high of $11.25. The firm has a market cap of $114.45, a P/E ratio of -2.04 and a beta of 1.01.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/11/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-redhill-biopharma-rdhl-share-price.html.
About RedHill Biopharma
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.